These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 31692299)

  • 41. MicroRNA-137 down-regulates KIT and inhibits small cell lung cancer cell proliferation.
    Li P; Ma L; Zhang Y; Ji F; Jin F
    Biomed Pharmacother; 2014 Feb; 68(1):7-12. PubMed ID: 24412084
    [TBL] [Abstract][Full Text] [Related]  

  • 42. YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer.
    Horie M; Saito A; Ohshima M; Suzuki HI; Nagase T
    Cancer Sci; 2016 Dec; 107(12):1755-1766. PubMed ID: 27627196
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Extracellular Vesicles Derived circSH3PXD2A Inhibits Chemoresistance of Small Cell Lung Cancer by miR-375-3p/YAP1.
    Chao F; Zhang Y; Lv L; Wei Y; Dou X; Chang N; Yi Q; Li M
    Int J Nanomedicine; 2023; 18():2989-3006. PubMed ID: 37304971
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular Subtypes of High-Grade Neuroendocrine Carcinoma (HGNEC): What is YAP1-Positive HGNEC?
    Kawai H; Matsuoka R; Ito T; Matsubara D
    Front Biosci (Landmark Ed); 2022 Mar; 27(3):108. PubMed ID: 35345340
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chemotherapy Resistance Molecular Mechanism in Small Cell Lung Cancer.
    Zhou J; Li Z; Li J; Gao B; Song W
    Curr Mol Med; 2019; 19(3):157-163. PubMed ID: 30813876
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
    Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
    Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
    [TBL] [Abstract][Full Text] [Related]  

  • 47. YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer.
    Li F; Xu Y; Liu B; Singh PK; Zhao W; Jin J; Han G; Scott AW; Dong X; Huo L; Ma L; Pizzi MP; Wang Y; Li Y; Harada K; Xie M; Skinner HD; Ding S; Wang L; Krishnan S; Johnson RL; Song S; Ajani JA
    Clin Cancer Res; 2019 Apr; 25(7):2264-2277. PubMed ID: 30563933
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Activation of endoplasmic reticulum stress promotes autophagy and apoptosis and reverses chemoresistance of human small cell lung cancer cells by inhibiting the PI3K/AKT/mTOR signaling pathway.
    Yu XS; Du J; Fan YJ; Liu FJ; Cao LL; Liang N; Xu DG; Zhang JD
    Oncotarget; 2016 Nov; 7(47):76827-76839. PubMed ID: 27765907
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin.
    Matsui S; Haruki T; Oshima Y; Kidokoro Y; Sakabe T; Umekita Y; Nakamura H
    Thorac Cancer; 2022 Apr; 13(8):1184-1192. PubMed ID: 35278040
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Zinc finger E-box-binding homeobox 2 (ZEB2) regulated by miR-200b contributes to multi-drug resistance of small cell lung cancer.
    Fang S; Zeng X; Zhu W; Tang R; Chao Y; Guo L
    Exp Mol Pathol; 2014 Jun; 96(3):438-44. PubMed ID: 24769353
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of DJ-1 as a contributor to multidrug resistance in human small-cell lung cancer using proteomic analysis.
    Gao H; Niu Y; Li M; Fang S; Guo L
    Int J Exp Pathol; 2017 Apr; 98(2):67-74. PubMed ID: 28580701
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long non-coding RNA HOTTIP promotes BCL-2 expression and induces chemoresistance in small cell lung cancer by sponging miR-216a.
    Sun Y; Hu B; Wang Q; Ye M; Qiu Q; Zhou Y; Zeng F; Zhang X; Guo Y; Guo L
    Cell Death Dis; 2018 Jan; 9(2):85. PubMed ID: 29367594
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    Li M; Lin A; Luo P; Shen W; Xiao D; Gou L; Zhang J; Guo L
    Aging (Albany NY); 2020 Jan; 12(2):1285-1303. PubMed ID: 31959735
    [TBL] [Abstract][Full Text] [Related]  

  • 54. FOXM1 is required for small cell lung cancer tumorigenesis and associated with poor clinical prognosis.
    Liang SK; Hsu CC; Song HL; Huang YC; Kuo CW; Yao X; Li CC; Yang HC; Hung YL; Chao SY; Wu SC; Tsai FR; Chen JK; Liao WN; Cheng SC; Tsou TC; Wang IC
    Oncogene; 2021 Jul; 40(30):4847-4858. PubMed ID: 34155349
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FIGNL1 is overexpressed in small cell lung cancer patients and enhances NCI-H446 cell resistance to cisplatin and etoposide.
    Ma J; Li J; Yao X; Lin S; Gu Y; Xu J; Deng Z; Ma W; Zhang H
    Oncol Rep; 2017 Apr; 37(4):1935-1942. PubMed ID: 28260065
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chemotherapy-Regulated microRNA-125-HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer.
    Yagishita S; Fujita Y; Kitazono S; Ko R; Nakadate Y; Sawada T; Kitamura Y; Shimoyama T; Maeda Y; Takahashi F; Takahashi K; Tamura T; Koizumi F
    Mol Cancer Ther; 2015 Jun; 14(6):1414-23. PubMed ID: 25833836
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of YAP1 in small cell lung cancer.
    Saito H; Tenjin Y; Yamada T; Kudoh S; Kudo N; Sanada M; Sato Y; Matsuo A; Orita Y; Ito T
    Hum Cell; 2022 Mar; 35(2):628-638. PubMed ID: 35072899
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
    Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC
    Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
    Chaib I; Karachaliou N; Pilotto S; Codony Servat J; Cai X; Li X; Drozdowskyj A; Servat CC; Yang J; Hu C; Cardona AF; Vivanco GL; Vergnenegre A; Sanchez JM; Provencio M; de Marinis F; Passaro A; Carcereny E; Reguart N; Campelo CG; Teixido C; Sperduti I; Rodriguez S; Lazzari C; Verlicchi A; de Aguirre I; Queralt C; Wei J; Estrada R; Puig de la Bellacasa R; Ramirez JL; Jacobson K; Ditzel HJ; Santarpia M; Viteri S; Molina MA; Zhou C; Cao P; Ma PC; Bivona TG; Rosell R
    J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28376152
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer.
    Li H; Wang H; Deng K; Han W; Hong B; Lin W
    Cancer Biomark; 2019; 24(1):51-59. PubMed ID: 30614795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.